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ABSTRACT
THE CHANGES OF FRUCTOSE-2,6-BISPHOSPHATE LEVEL IN
TRANSGENIC MICE CAUSING CARDIOMYOPATHY

Jianxun Wang

June 19, 2007

Heart failure is recognized as a major cause of death among
diabetics. In type I and II diabetes, glucose uptake, glycolysis and pyruvate
oxidation are impaired, and fatty acid utilization increases These alterations
in metabolism contribute toward cardiac contractile function. There is a gap
in

our

understanding

fructose-2,6-bisphosphate
cardiac-specific

on

how

alterations

(F-2,6-P 2) affects

overexpression

of

PFK-2

in

glycolytic

cardiac

metabolite

dysfunction.

(phosphofructose

Two

kinase-2)

transgenic models were used to investigate the role of altered metabolism by
F-2,6-P2 in provoking cardiomyopathy. One model is with the PFK-2 kinase
active and phosphatase inactive enzyme called MK and another model is the
PFK-2 kinase inactive and phosphatase active enzyme called Mb. The effect
of PFf<2 transgenes was evaluated by Langendorff -perfused heart in vitro.
Cardiomyopathy was assessed by measurement of heart to body weight
ratio and cardiac histology. The study shows that changes in F-2,6-P2 level
could mduce cardiac hypertrophy and fib:rosis and cause cardiac dysfunction,
and may be important to development of diabetic cardiomyopathy.
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INTRODUCTION

Significance and Background
Diabetes mellitus is the worlds fastest growing disease. Almost
20.8 million children and adults in the United States have diabetes. Type 1
diabetes can not produce insulin due to pancreatic

~-cell

dysfunction and

type 2 diabetes can not properly use insulin due to insulin resistance and
pancreatic

~-cell

dysfunction. An association between diabetes and cardiac

disease was first recognized in the late 1800s.
Framingham Heart Study

1. 2

More recently, the

provided conclusive evidence of the role of

diabetes in heart failure: in a prospective study of 5,000 individuals, the risk
of heart failure was increased in diabetic men and women by two- and
five-fold respectively and heart failure is now recognized as a major cause of
death

among

cardiomyopathy,

diabetics
leading

3

Diabetic
to

patients

congestive

usually
heart

exhibit diabetic
failure.

Diabetic

cardiomyopathy is characterized by impaired cardiac contractility and poor
myocardial performance without vascular or valvular disease

4

Several

metabolic complications which are involved in diabetic cardiomyopathy are
common to both types1 and 2 diabetes. For example, hyperglycemia and
elevated free fatty acids (FFA) are present in type 1 and 2 diabetes. Although

the time course of developing ventricular dysfunction may be different, the
cardiac consequences of both types of diabetes are similar. However, the

mechanisms by which diabetic cardiomyopathy develops is still unclear. A
better understanding of cardiomyopathy development during diabetes can
provide information for the treatment of cardiomyopathy.
Under normal conditions, fatty acids provide 70% and glucose and
lactate provide 30% energy for heart 5. 6 7. (see figure 1) In pathophysiologic
conditions, such as cardiomyopathy, the heart can rapidly switch its
substrates between glucose and fatty acids to ensure continuous ATP
generation for maintaining heart function 8.

9. 10. 11

12.

13.

14. However, this

transition has also been associated with deleterious consequences. In type I
and type II diabetes mellitus, glucose uptake, glycolysis and pyruvate
oxidation are impaired, and fatty acid utilization increases. This alteration in
metabolism contributes toward cardiac contractile dysfunction 15, other
factors contributing to diabetic cardiomyopathy, such as changes of Ca 2+
homeostasis, decreased cardiac efficiency,

liptoxicity and

myocardial

mitochondrial damage, have also been linked to alterations in myocardial
metabolism. These changes in cardiac metabolism are learly events and
precede the development of cardiomyopath/ 6 . Furthermore, normalizing
cardiac metabolism in diabetic animals can reverse ttle development of
cardiomyopathi 7 18.19 . Therefore, a proper balance of cardiac metabolism
is a key factor to maintaining a healthy heart. Disruption of the balance of
myocardial metabolism by high glucose and/or by hyperlipidemia could result
in cardiomyopathy.
There is a gap in our understanding of how alterations in the
glycolytic metabolite, fructose-2,6··biphosphate (F-2,6-P2), affects cardiac
function. F-2,6-P2 is a key regulator of phosphofructose kinase-1 (PFK-1),

2

one of the rate-limiting steps of glycolysis ( see figure 1). In hepatic cells,
increased F-2,6-P2 can also modify expression of genes involved in
carbohydrate

mE~tabolism,

increasing

expression

of

!~Iucokinase

and

inhibiting expression of glucose-6-phosphatase, meanwhile the expression
of two key lipogenic enzymes, acetyl-eoA carboxylase and fatty acid
synthetase, is reduced. 47 Therefore, changes in F-2,6-P2 levels in the heart
may disturb

thE~

balance of cardiac metabolism.

Glucose upta.ce and utilization

In the heart, cardiac glucose uptake is driven by a glucose gradient
and is dependent on the density of sarcolemmal glucose transporters such as
Glut1 and Glut4. Under basal conditions without insulin stimulation, Glut4 is
located in an intracellular pool and Glut1 is primarily located on the sarcolemma
membrane, therefore, Glut1 transporter regulates basal glucose uptake. Upon
activation by insulin, however, Glut4 will translocate to the cell membrane to
transport glucose 2o 21.22, as a major contributor for glucose uptake. After
gluCOSE! enters the cardiornyoctye glycolysis occurs. Glycolysis is controlled by
a network of enzymes including hexokinase, PFK-1 and PFK-2. After glycolysis,
pyruvate can enter mitochondria for oxidation. Glycolysis is far more
complicated than just breaking down glucose. ATP derived from glycolysis
seems to have a preferential role in maintaining normal conductance for
calcium, potassium and sodium ions in the cell membrane:23· 24. 25. In isolated
perfused hearts., increased utilization of glucose can decrease ischemic
damage while decreased utilization of glucose tends to sensitize the heart to
ischemia 50.
The glycolytic rate is lower in diabetics. A low rate of glycolysis will

impact heart function, even leading to cardiomyopath y 15. F-2,6-P2 is a key
regulator of

PFK-1, one of the rate limiting steps of glycolysis. Decreased

F-2,6-P 2 mimics the situation in diabetes and will reduce the glycolytic rate. In
diabetic states, hepatic F-2,6-P2 levels are low due to insulin deficiency, or
relatively low due to insulin resistance 49 . If this low level of hepatic F-2,6-P2 is
raised, however, blood glucose levels could be reduced, and many of the
metabolic consHquences of type 2 diabetes could be ameliorated 26 27.
Proposed mechanisms for functional recovery by increased F-2,6-P2 are that
F-2,6-P 2 increases AKT phosphorylation, favors glycolysis and suppresses
gluconeogenesis through allosteric activation of PFK1

28.

Therefore, decreased

F-2,6-P2, leading to reduction of glycolysis and ATP, will dHcrease ion channel
activity on the cardiomyocyte membrane and reduce membrane potential. We
therefore hypothesize that decreased F-2,6-P2 in the Mb transgenic model
mouse will result in cardiomyopathy.
Hyperglycemia can provoke glucotoxicity, causing cardiac tissuH
injury due to excess production of reactive oxygen species (ROS), leading to
release of cytochrome C and activation of Poly (ADP-ribosH) polymerase-1
(PARP) 29. PARP, through inhibition of glyceraldehyde phosphate
dehydrogenase (GAPDH), diverts glucose from glycolytic pathways to other
pathways, including polyol and hexosamine pathway flux

30.

In the polyol

pathway the cell will be depleted of NADPH and GSH, and oxidative stress will
increase. In the hexosamine pathway, activities of some transcriptional factors
such as SP1 will be

affectE~d

and gene expression profiles will be altered.

Increased F-2,6-P;: can increase glycolytic rate and decrease intracellular
glucose levels. In the MK transgenic mouse, this decrease of intracellular

4

glucose could facilitate glucose uptake by the transporter (:;lut1 using the
energy of the glucose gradient potential mimicking the high
diabetes,

exhibitin~J

!~Iucose

level of

glucotoxicity. We hypothesize that excess F-2,6-P 2 , through

multiple pathways such as the polyol and hexosamine pathways, contributes to
the development of cardiomyopathy.
Fatty acid uptake and utilization
Three fatty acid (FA) transport proteins have be'en identified In the
heart,: C036, FA transport protein (FATP) and FA binding protein plasma
membrane (F/~BPpm)31. Once the FA enters cardiomyocytes, the FA will be
esterfied by acyl-CoA synthase (ACS), the fatty acyl··CoA can then be
transported into mitochondria for oxidation or stored as tri91ycerides (Tg). In
normal heart, there is a balance between lipogenesis and lipolysis to control
intracellular T~I level 32. If FA supply is far more than cellular oxidative
capacity, Tg can accumulate and lipotoxictiy follows. For

E~xample,

transgenic

mice overexpressing cardiac ACS, FATP or LPL ( lipoprotein lipase)
demonstrated that increased FA uptake and utilization of FA and/or lipid
accumulation correlated well with contractile dysfunction 33 34,35 In human
diabetic patients, increased FA utilization is associated with augmented
cardiac

oxygE~n

consumption and reduced cardiac efficiency. Reduction of

cardiac efficiency and increased oxygen demand makes Ule heart especially
vulnerable to damage following

increased

workloads or ischemia. 15

Accumulation of FA leads to augmented intracellular FA derivatives, such as
fatty acyl-CoA, diacylglycerol and ceramide. 36
activate a serine kinase cascade which

37.

38 ThHse FA metabolites

phosphorylate~s

serine of insulin

IR~S·-1

reduces tyrosine

receptor substrate (IRS). Serine phosphorylation of

phosphorylation of IRS-'l, resulting in insulin resistanc:e,39 40. 41, 42, 43
Therefore, decreased F-2,6-P2 will reduce glycolysis and !Jlucose oxidation
and potentially stimulate cardiomocytes to transport more fatty acids to
compensate for the deficiency of ATP, leading to accumulation of FA
metabolites and rE!sulting iln cardiomyopathy (see figure 3),
Cross talk between fatty acid and glucose utilization

Healthy hearts derive most of their energy from frE!e fatty acids and
only a small proportion from circulating glucose, However, diabetic hearts use
more fat and IE~ss glucose than normal hearts 44 , For example, FA oxidation
accounts for 93% of calculated ATP production in diabetic hearts compared
with 64% in control hearts, Glycolysis accounts for only 4% of ATP production
in diabetic hearts relative to 11 % in normal hearts, and glucose oxidation
accounts for only 3% of ATP production compared with 25% in control
hearts,45 In contrast to diabetic hearts, there is an increase in cardiac glucose
usage and a

rE~duction

in fat consumption after a myocardial infarction,

Overexpression of LPL in the heart accelerates FA uptake, conversely, tissue
specific knockout of LPL causes heart to prefer glucose, The presence of
glucose also can reduce fatty acid metabolism, probably by increaSing
intracellular level of malonyl-eoA ( see figure 2),

ThesE=~

alterations of

cardiac metabolism are important causative factors in the development of
cardiomyopathy, as shown in the perfused hearts from leptin receptor deficient
(db/db) mice and transgenic db/db-hGLUt4 mice which overexpress Glut4,
Reduced fasting hyperglycemia and improved glucose disposal after an oral
glucose challenge in db/db-Glut4 mice was observed when compared to db/db
mice 48 while reduced contractile performance in db/db mice was also

6

completely normalized in db/db-Glut4 mice. 45
Some studies show that activation of cardiac PPAR-a not only favors
FA oxidation but also inhibits glucose uptake' and utilization, leading to
augmented susceptibility to ischemic damage.
prevents suppression of GLUt4 expression and

Knockout of cardiac PPAR-a
glucosf~

uptake by elevated

plasma FA and improves myocardial recovery from ischemia,46 the
mechanisms that explain how changes of cardiac metabolism are involved in
diabetic cardiomyopathy are still unclear. We hypothesize that decreased

F-2,6-P:< will shift the cardiac metabolite from glucose to F'A utilization and
increased

F-2~,6-P2

shift the cardiac metabolite from FA to

~llucose

utilization.

The shift between glucose and fatty acid utilization may cause abnormal
cardiac function e.g. heart hypertrophy, heart failure and cardiomyopathy.

7

FIGURE 1
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Fig.1. A balance between glucose and fat consumption exists in the healthy
cardiomyocyte. Glucose is transported into cytosol by glucose transporters 1
and 4, and provides 30% of the energy for the heart through glycolysis and
glucose oxidation as shown in the left pathway. Fatty acid is transported into
cytosol by transporters FAT/CD36 etc. for fatty acid oxidation, and provides
70% the energy for the heart as shown in the right pathway.
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FIGURE 2
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Fig.2. Randle cycle. Glucose metabolites interact with fatty acid metabolites
within mitochondria and cytosol. Fatty acid-CoA in cytosol is transported into
the mitochondrion by transporters CPT I and CPT II. Acetyl-CoA can be
produced from fatty acid in mitochondria via j3 -oxidation. The acety-CoA
derived from

fatty

acid

oxidation

inhibits

the

activity of pyruvate

dehydrogenase complex (PDC) to reduce glucose oxidation, and also enters
the TCA cycle for the synthesis of citrate. The citrate can diffuse out of the
mitochondrion to the cytosol, inhibiting the activity of PFK-1 which will result
in the accumulation of G6P. The accumulated G6P will inhibit the activity of

9

hexokinase (HK), and meanwhile the accumulated fatty acid-CoA in the
cytosol can also inhibit the activity of HK, with overall reduction of glycolysis
and

glucose oxidation.

Acetyl-CoA derived from

glucose can form

acetyl-carnitine which is transported out of the mitochondrion to release the
glucose-derived acetyl-CoA, favoring synthesis of malonyl-CoA in the cytosol.
The increase of malony-CoA will directly inhibit the activity of the transporter
CPT I, leading to reduction of the fatty acid oxidation.
6) Indicates inhibition.
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FIGURE 3
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Fig.3. The signal pathways induced by the intracellular accumulation of fatty
acids are involved in the development of heart failure. The pathways can be
divided into three parts: cardiac dysfunction, apoptosis and insulin resistance.
Fatty acid acyl-GoA accumulation in the cytosol can increase the expression
of PPAR a , resulting in an increase of the expression of slow contractile
protein f:\ - myosin heavy chain, and can activation of K-ATP channel opening,
leading to a decrease of ca 2 + flux. Both the increase of f:\-MHG and
decrease of ca 2 + flux will decrease cardiac contractility and cardiac
dysfunction follows. Fatty acid acyl-GoA accumulation in the cytosol can
raise intracellular oxidative stress (ROS) damaging the mitochondria and
stimulating the synthesis of ceramide, with a resulting increase in caspase 3

II

activity and cytochrome C release which result in an increase in apoptosis.
Insulin resistance also can be induced by the accumulation of fatty acid
acyl-CoA

through

upregulation,

~

decreasing

phosphor-AKT

indicates downregulation.
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signalingl.

indicates

METHODS AND MATERIALS

1. Development of transgenic mice
The

bifunctional

enzyme

6-phosphofructo-2-k.inase/fructose-2,6-bisphosphatase

(PFK2)

controls

levels of F-2,6-P2 by catalyzing two opposing reactions: F-6-P + ATP
F-2,6-P2 + ADP and F-2,6-P2

~

---'t

F-6-P + PII. 1.6 kb Kpnl/Hindlll fragments of

the kinase mutant PFK2 cDNA or the bisphosphatase mutant PFK2 cDNA
was produced by polymerase chain reaction. An insertion DNA fragment for
cardiac specific expression was obtained by cutting a ligated plasmid in
which the deficient PFK2 cDNA was inserted behind the a-myosin heavy
chain

promoter.

The

insertion

DNA

fragments

for

kinase

active/bisphosphatase mutant PFK2 or kinase mutantlbisphosphatase active
were injected into fertilized embryos to produce

trans~lenic

animals The

transgenes were designated Mk (for the MHC promoter and the kinase active
with bisphosphatase deficient PFK2 gene) and Mb (for the MHC promoter
and the bisphosphatase active with kinase deficient PFK2 gene).Transgenic
mice

were

produced

on

the

FVB

background

and

maintained

as

heterozygotes by breeding to FVB mice. All procedures conformed to the
Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised 1996) and

13

were approved by the USDA certified institutional animal care committee.
Male mice aged 90-130 days were used in the following studies.

2. Analysis of F-2,6-P2 content in transg,enic mice
The concentration of F-2,6-P2 was measured in the three groups of
mice: FVB control, Mb and Mk. First, 0.1 g of heart tissue was homogenized
in 10 volumes (1 ml) of 50 mM sodium hydroxide, then the tissue was
solubilized by heating at 80 a C for five minutes. The solution was cooled on
ice, neutralized with 100 III of 1M ice cold acetic acid in 20 mM Hepes and
the supernatant containing F-2,6-P2 was collected by centrifugation at 8000g
for 10 minutes. 0.25 ml of the reaction mixture (100 mM TES, pH 8.0, 6 111M
MgCI 2, 1 mM EOTA , 0.1 mM OTT and 0.22 mM NAOH) was mixed with 20
ul of the supernatant, then 25 ul of 50 mM NaPPi (Sodium pyrophosphate)
was added. The changes in absorbance for 10 min at 340nm were recorded
along with F-2,6-P2 standards.

3. Cardiac perfusion
Mice were anesthetized with ketarnine (50 mg/kg, i.p.) and xylazine

(2.5 mg/kg, i.p.) and given heparin (10 U/g, i.p.). The hearts were
retrogradely perfused at 2 ml/min with Krebs-Henseleit buffer (KH) consisting
of 120 mM NaCI, 20 mM NaHC0 3 , 4.6 mM KCI, 1.2 mM KH 2P04 , 1.2 mM
MgCb,

1!

.25 mM CaCb 5 mM glucose and 0.25 J..lCilml of [5- 3 Hjglucose.

Throughout the perfusion KH buffer was continuously equilibrated with 95%
0 2/5% CO 2 which maintained a pH of 7.4 and temperature was maintained at

3rC. The hearts were paced throughout the procedure at 6 Hz (6 V, 3 ms).
For studying the effect of insulin, baseline

14

!~Iycolysis

was determined for the

first 30 min followed by SO min in the presence of 200 /-lU/ml insulin.
Glycolysis in the presence of palmitate was measured by bringing the
perfusatH to O.4mM palmitate by addition of 1/20th volume of 8mM palmitate
bound to 10% BSA in KH buffer. Perfusion pressure was monitored on a
Gould/Statham p23Db physiological pressure transducer. Contractile force
was measured with a Grass FT03 force transducer hooked to the apex of the
heart. Transducers were connected to a ETH 400 bridge amplifier which fed
into a Powerlab/400 amplifier. Data were analyzed using AD InstrumEmts
Chart for Windows version 3.3.S.

4. Measurement of glycolysis and lactate production

Tritiated water produced from [S-3H] glucose during the perfusion
was determined by diffusion. A 400-1.11 sample of cardiac effluent and 2S pi of
0.6 N HCI were added to 1.S-ml tubes that WHre placed inside 20-ml
scintillation vials containing 2 ml water. Vials were incubated for 72 h at 3rC.
The inside tube was removed and Ecolite scintillation fluid was added for
counting. Effluent from each time point was assayed in triplicate. For each
experimE~nt,

background counts were determined by performing the S8lme

equilibration with perfusion media that had not passed through the heart.
Diffusion efficiency was also measured in each experiment using tritiated
water. Lactate concentration was measured in a 6-fold diluted effluent using
Sigma kit 826-B.

5. Isolation of adult mouse ventricular myocytes 97 •
Mb, Mk and FVB control mice were anesthetized with ketamine (SO

15

mg/kg, i.p.) and xylazine (2.5 mg/kg, i.p.) and given heparin (10 U/g, i.p.).
Their hearts were rapidly removed and perfused at constant pressure
(100 cmH 20) at 3rC for -3 min with a Ca 2+-free bicarbonate-based buffer
containing (in mM) 120 NaCI, 5.4 KCI, 1.2 MgS04 , 1.2 NaH 2P0 4 , 5.6 glucose,
20 NaHC0 3 , 10 2,3-butanedione monoxime (BDM; Sigma), and 5 taurine
(Sigma),

with oxygenation (5% C0 2/95% O2). Then the perfusate buffer

was changed to digestion buffer containing Ca 2+-free bicarbonate buffer plus
collagenase (0.5mg/ml) and CaCI2 0.05mM for 7- 10min until the hearts
became swollen and flaccid. The hearts were removed from cannulation and
the left ventricles were separated with blunt forceps in 2 ml digestion buffer.
The minced tissues were gently agitated by repeated pipette aspiration,
filtered through a 140 IJm nylon mesh and transferred into conical tubes
containing 10 ml of suspension buffer I containing Ca:2+ -free bicarbonate
buffer plus CaCb 0.125mM and BSA 5mg/ml. After the myocytes were
pelleted by centrifuging at 300rpm for -10 min, the supernatant was
aspirated and the myocytes were resuspended in suspension buffer II
containing Ca 2+-free bicarbonate buffer plus CaCb 0.250mM and BSA
5rng/ml. The final cell pellet was suspended in suspension buffer III
containing Ca 2+-free bicarbonate buffer plus CaCI 2 0 ..500mM and BSA
5mg/ml. The fresh isolated cardiomyocytes were collected by centrifuging at

300rpm for 1Omin.To reduce contamination, the perfusion setup was washed
with 70% alcohol and then rinsed three times with sterillized distilled water
before cannulation. All the solutions were filtered (0.2-lJm filter) and
equilibrated with 95% Or5% CO2 for at least 20 min before use.
6. Culture of adult mouse cardiac myocytes 97 .

16

Culture dishes were precoated for 8h with 10 IJg/ml mouse laminin
(GIBCO)

in

phosphate-buffered

saline

(PBS;

GIBCO)

with

1%

penicillin-streptomycin (PS; GIBCO) at room temperature. Freshly isolated
cardiac myocytes were suspended in minimal essential medium (MEM;

Si~lma M1018) containing 1.2 mM Ca?+, 2.5% preselected fetal bovine serum
(FBS; GIBCO), and 1% PS (pH 7.35-7.45). The myocytes were plated at
4

2

1 >: 10 cells/cm in MEM containingl 2.5% FBS and 1% PS. After 1 h of
culture in a 5% CO 2 incubator at 37°C, the medium was changed to FBS-free
MEM and this was changed every 48 h during culture.

7. Western Blotting
After the cardiomyocytes wel"e cultured for 1 day, insulin was added
to each dish at a concentration of 0,0.1, 1,3,5, 10,20,301 or 90nM for 40min.
The cultured cardiomyocytes were collected and lysed by lysis buffer
containing 2% SOS, 10% glycerol, and 62.5 mmollL Tris (pH 7.0) and then
sonicated. Cell proteins were collected by centrifuging at 12 000 rpm at 4°C
for 10 minutes. The protein concentration was determined, and the sample
was mixed with loading buffer (40 mmol/L Tris-Hel, pH 6 . 8, 1% SOS, 50
mmol/L dithiothreitol, 7.5% glycerol, 0.003% bromophenol blue) and heated
at 95°C for 5 minutes and then subjected to electrophoresis on a SOS-PAGE
gel at 120 V. After electrophoresis , the proteins were transfHrred to a
nitrocellulose membrane in transfer buffer containing 20 rnmollL Tris, 152

mrnol/L glycine, and 20% methanoL The membranes

werE~

rinsed briefly in

PBS and blocked in blocking buffer (5% milk and 0.5% BSA) at room
temperature for 2 hours . After blockin<g, the membranes were incubated with
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antibodies against P-IR, P-AKT, P-4EBP, P-GSK-3b and actin, thEm washed
3 times with TBS-T containing 0.05% Tween-20 and incubated with
secondary horseradish peroxidase-conjugated antibody for 1 hour. Signal
detection was facilitated with enhanced chemiluminescence (ECl kit,
Amersham). Actin expression was used as a loading control.

8. Phenylephrine administration by pump implantation

Two-month old FVB control, Mk and Mb7 mice (three woups) were
used. Each group of mice was treated with phenylephrine (PE) or PBS
(vehicle control) for 28 days. Alzet miniosmotic pumps (Alza Corp., Mountain
View, CA, USA) containing PE (50 mg/kg/day) or PBS were surgically
inserted dorsally and subcutaneously under anesthesia by mixture of
ketamine (50 mg/kg) and xylazine (2.5 mg/kg) given i.p.

9. Histological Study

The mice were anesthetized with a combination of ketamine
(50 mg/kg) and xylazine (2.5 mg/kg, i.p.), the hearts were excised and
immersed in formalin buffer over night, and then the hearts were embedded
in paraffin. 5 /-lm heart sections were placed on slides, deparafflinized and
stained with hematoxylin/eosin for histology and with picric acid for analysis
of collagen accumulation. The solution of picric acid (saturated, 1Q/b) contains

O. 'I % Sirius red for staining collagen and 0.1 % Fast Green for staining
non-collagen proteins. The sections were examined with Nikon Eclipse E600
by light microscopy and images were acquired with SPOT camera. The
quantitative analysis of the interstitial fibrosis were done by Adobe
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Photoshop software.

10. Statistical Analysis

Data are described by mean ±SE for normally distributed variables.
For all statistical analyses, 1-way or 2-way ANOVA model and Tukey's
post-hoc test were performed for repeated measures. Single comparisons
were performed by Student's t-test. The difference are considered significant
when P<O.05.
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RESULTS
The data are divided into three parts: in vivo studies, Langendorff
perfused heart studies and in vitro cultured cardiomyocyte studies. Figures 4,
6 and 11 were provided by Dr. Rajakumar Donthi Figures 12 and 13 were
provided by Qianwen Wang. The author is
15,16 and 17.

I~esponsible

for figures 13, 9, 10, 14,

Dr. Rajakumar Donthi and the author collaborated on the

research shown in figures 5 and 7.

1. In Vivo analysis

1.1 The content of F-2,6-P2 in FVB, Mk and Mb mice is shown in
figure 4. In Mk mice, the kinase active/bisphosphatase inactive PFK-2
mutant cDNA was transfected into FVB background mice and was
overexpressed specifically in hearts via a driver of
( (j

(j

-myosin heavy chain

-MHC) promoter. In Mb mice, the kinase inactive/bisphosphatase active

PFK-2 mutant cDNA was transfected into FVB background mice and was
overexpressed specifically in hearts being driven by

(j

-MHC promoter. FVB

mice were used as wild type control. F-2,6-P2 increased 3 fold in Mk mice
and decreased to 50% in Mb mice compared to FVB control mice.
1.2 The measurement of heart to body weight ratio. In Mk and Mb
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mice, the ratio of heart weight to body weight significantly increased 15% and
5% respectively compared to that in FVB control mice as shown in figure 5.

1.3 Histology analysis in FVB, Mb and Mk mice is shown in figure 6
and figure 7. Cardiac fibrosis was significantly increased in both Mk and Mb
transgenic hearts compared to FVB control mice.

1.4 The effects of treatment with phenylephrine on Mk, Mb and FVB
control mice is shown in figures 8, 9 and 10. Phenylephrine treatment
increased cardiac afterload, inducing heart failure. At a dose of 50rng/kg/day
of phenylephrine, Mk and Mb transgenic mice had higher mortality than FVB
control mice. The death of cardiomyocytes by HE staining was observed in
Mk and Mb hearts but not in FVB control hearts. Furthermore, hearts from
Mb mice seemed weaker than Mk mice.

2. Langendorff perfused heart data

2.1 The effect of Mb transgene on cardiac glycolysis was assessed
in Langendorff-perfused hearts by measuriing the consumption of 5-tritiated
glucose and the production of lactate. 3H2 0 is released from the metabolism
of [5·· 3H] glucose by the triose-phosphate isomerase and the enolase steps of
the ~llycolytic pathway. As shown in figure "11, both 3H 20 and lactate release
were significantly reduced in Mb transgenic hearts. Perfusion pressure was
constant at 65 mm Hg and flow rate was stable and equal in Mb and FVB
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FIGURE4
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Fig.4. F-2 ,6-P2 content in Mk, Mb and FVB control mice. F-2,6-P2 increased
significantly, almost three fold higher in Mk than in FVB control whi le F-2,6-P2
content in Mb mice decreased significantly to 50% of FVB control. The
values shown are mean ±SE and were analyzed by one way ANOVA (*:
p<0 .05, n=4/each group)
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FIGURE 5

Heart- body weight ra t io
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Fig .5.The figure shows the heart to bod y weight ratio in FVB, Mb and Mk
mi ce. The rati o of heart to body weight significantly in creased 5% in Mb mi ce
and 15% in Mk mice com pa red to FVB control. Therefore Mb and Mk hearts
showed mild hype rtrophy. Th e data were analyzed by one way ANOVA
analysis. ' : p < 0.01 , •• : p<0.05 compared to FVB.
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FIGURE 6
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Fig.6. Co llagen accumulation in FVB and Mb hearts. Sirius red staining was
visualized at x40 and photographed. A, representative collagen stain ing for
FVB and Mb mice . B, scoring of collagen content in 14 photographs taken
from FVB (3) and Mb (4) mouse hearts . Staining was rated by a blind
observer on a sca le of 0-2, where 0 indicates mild, 1 increased , and 2 severe
interstitial accumulation of co llagen. The va lues shown are mean ± S. E. and
were analyzed by ANOVA on Rank test (, p < 0.01).
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FIGURE 7
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Fig . 7. Histology of FVB and Mk hearts. Collagen accumulation was visualized by
Sirius red staining at x40 . A, representative Sirius red staining of FVB and Mk
hearts. B, scoring of collagen content in 30 photographs taken from FVB (3) and
Mk (3) mouse hearts. Staining intensity was rated by Adobe Photoshop software .
The values shown are mean ± S.E. and were analyzed by Student's test (: p <
0.001 ).
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FIGURE 8

Survival curves
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Fig.8. Survival curves of Mb, Mk and FVB mice following treatment of
phenylephrine for 28 days (implantation of pumps at dose of 50mg/kg/day).
Higher mortalities in transgenic mice Mb and Mk were found; moreover, the
mortality of Mb mice was higher than of Mk mice . Unfortunately, No significant
differences were found within the comparisons of Mk vs. Mb, Mk vs . FVB and FVB
vs . Mb through Ka plan-Meier survival analysis (Mb vs . FVB ' , p=O.067, n=8/
each group ). It is possible that if more mice are tested, a significant difference
may be observed .
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FIGURE 9

FVB

Mb

Fig.9 . HE stainin g on FVB control, Mb and Mk hea rts after being treated with
phenylephrin e for 3 da ys. The HE staining was visualized at x40 and
photographed . The death of ca rdiomyoctyes was found in Mb and Mk not in FVB
control mi ce . The hearts from Mk and Mb mice see med more susceptible to
phenyl ephrin e treatm ent than that from FVB co ntrol mice.
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FIGURE 10

PE treatment

Saline control

Fig.1O. Histology of FVB hearts with phenylephrine and saline treatment
respective ly. Sirius red staining was visua lized at x40 and photographed . Fibrosis
accumu lated in the heart from FVB mice with PE treatment for 28 days compared
to that from FVB control mice with sa line treatment
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hearts throughout the experimEmt. After addition of insulin to the perfusate,
the difference in metabolism between transgenic and control hearts became
even greater because of a clearly diminished response to insulin in
transgenic hearts (Fig. 11 C and D). At the end of the 50-min perfusion with
insulin, 5-tritiated glucose consumption was increased by 70% in FVB hearts
but only by 34% in transgenic hearts (Fig. 11 C). Similarly, lactate output was
increased by 90% in FVB hearts but only by 25% in Mb hearts (Fig. 11 D).
The differences in the response to insulin were significant (p < 0.02).
2.2 Effect of Kinase Active PFK-2 on Cardiac Glucose Metabolism

The effect of Mk transgene on glycolysis was assessed in
Langendroff-perfused hearts by measuring metabolism of 5-tritiated glucose
and lactate production. Glycolysis was measured by the release of tritiated
water through the triose phosphate isomerase reaction.

As shown in

Figure 12, in the presence or absence of palmitate, the release of 3 H2 0 and
lactate was significantly elevated in Mk transgenic hearts compared to
control hearts. The Mk effect was evident both before and after addition of
insulin. The increase in glycolysis did not appear to be related to contractility
or perfusion pressure: no significant difference was observed for contractility
between transgenic and control hearts at any time point (data not shown).
Also in both groups, perfusion pressure averaged 65 mm Hg while the flow
rate was maintained at 2rnl/min.
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~Iraphs

show the percent increase in glycolysis

(C) and lactate release (0) produced by the 50min stimulation with insulin.
Values shown are mean ± S.E. for FVB (12) and Mb (14) mice. Panels A and

B were analyzed by two-way repeated measurBS ANOVA followed by Tukey
post-hoc test. Panels C and 0 were analyzed by Student's

.. , p < 0.002; #, p < 0.02.
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t test.

., p < 0.05;

To determine if the transgene altered the effect of palmitate, the results for
tritiated water release were replotted in Figure "13, As shown in Figure 13A
palmitate significantly reduced glycolysis in FVB hearts but had no clear
effect on glycolysis in Mk transgenic hearts (Figlure 13B),

3. In Vitro data on insulin signaling

Cardiomyocytes

were

challenged

by

insulin

at

different

concentrations (0, 0,1, 1,0, 3,0, 5,0, 10,0, 20,0, 30.0 and 90.0 nM). Total
proteins from the cultured cardliomyocytes were isolated by lysis buffer and
used for Western blot analysis. The insulin signals including Phospho-AKT
(p-AKT),

Phospho-insulin

Phospho-GSK-3b were

receptor

(P-IH),

Phospho-4EBP1

and

investi~lated,

3,1 P-AKT and P-IR signals in FVB, Mb and Mk mice (see figure 14)
P-AKT signals in cultured cardiomyocytes were significantly higher
in Mk and Mb transgenic mice when challenged by different concentrations of
insulin compared to FVB control mice, The maximum increase of P-AKT signal
in Mk and Mb mice reached 20% at 20 nM insulin, P-AKT

si~lnal

of Mk mice was

similar to that of Mb mice, EC 50 for P-AKT in Mk mice was 2,AnM and maximum
response in Mk mice was 0,24, EC 50 and maximum response for P-AKT in Mb
mice were 2,3nM and 0.252 respectively, and EC E10 and maximum response for
P-AKT in FVB control mice were 2,5nM and 0,188 respectively, The response of
P-IR to insulin stimulation among the three group mice was similar,
3.2 Replot of P-IR curve vs. P-AKT curve in FV8, Mb and Mk mice
(see figure 15)
P-AKT signals reached peak level at 20nM of insulin stimulation in
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all three group mice. Surprisingly the increase in P-AKT was evident at 1nM
while the P-IR response did not begin until 5nM insulin.
3.3 P-4EBP1 signal in FVB, Mb and MK mice in figure 16
P-4EBP1 is a downstream product of P-AKT. According to previous
results, insulin concentration of 10 and 20 nM was chosen. P-4EBP1 signal was
significantly increased in all three groups of mice with insulin treatment
compared to non-insulin stimulated mice. No significant diffnrences were found
among the three groups of mice with insulin treatment.
3.4 P-GSK-3b signal in FVB, Mb and MI{ mice as shown in figure 17.
P-GSK-3b is another downstream product of P-AKT. The insulin
concentration of 10 and 20 nM was also chosen. P-Gi,sK-3b signal was
significantly increased in all three groups of mice with insulin treatment
compared to non-insulin stimulated mice. No significant differences were found
among the three groups of mice with insulin treatment.
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FIGURE 12
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Fig.12. Effect of kinase active PFK-2 on glycolysis with or without 0.4 mM
palmitate before and after addition of 200I-lU/ml insulin. I-liearts were isolated
and glycolysis was measured using 5- 3 H-glucose (A) Glycolysis without
palmitate. (B) Glycolysis with palmitate
palmitate (0) Lactate release with palmitate.

(C) LactaIe release without
The valuBs for FVB and Mk

were compared by two way ANOVA (*: p < 0.05). Values shown are means ±
SE for at least 5 mice per point.
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FIGURE 13
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Figure 12.
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DatE11 are replotted from

FIGURE 14
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Fig .14. Log concentration-response curves for P-AKT and P-IR signa ls in
cultured cardiomyocytes when stimu lated by different concentrations of
insu lin . The signa ls of P-AKT in A were found significantly higher in Mk and
Mb mice compared to FVB mice. The maximum in crease of P-AKT signa ls in
Mk and Mb mice reached 20%. ECso of P-AKT in Mk mice was 2.4nM and
maximum response in Mk mice was 0.24. ECso and maximum response for
P-AKT in Mb mice were 2.3nM and 0.252 respective ly, and ECso and
maximum response for P-AKT in FVB contro l mice were 2.5nM and 0.188
respective ly No significance was found between Mk and Mb mice . In B, it is
shown that the response of P-IR to insulin stimu lation was sim ilar and no
significant differences were found among the three groups. (*, **, p<0.05 by
2-way ANOVA ana lysis vs . FVB control mice)
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FIGURE 15
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FIGURE 16
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FIGURE 17
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Fig.17. P-GSK-3b in the cultured cardiomyocytes challenged by insulin at 0,
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stimulated myocytes. No significant differences were found among the three
groups of mice with insulin treatment (*, p<0 .05)
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DISCUSSION
Our data show that the F:-2,6-P2 content in Mk hearts was increased
3 fold compared to FVB control, in contrast F-2,6-P2 in I\/Ib hearts decreased
to 50% of control. F-2,6-P2 is a potent stimulator of the ,glycolytic regulatory
enzyme PFK1. The glycolytic effect of the Mk and Mb transgene was
assessed in Langendorff-perfused hearts by the release of tritiated water
from 5-tritiated glucose through the triose phosphate isomerase reaction,
while lactate was also detected. As shown in figure 12, in the presence or
absence of palmitate, the release of 3H 20 and lactate was significantly
elevated in Mk transgenic hearts compared to control hearts. Whereas in Mb
transgenic hearts shown in figure 11, the release of 3H 20 and lactate
decreased significantly in the absence of palmitate. The Mk and Mb
transgenic effects were evident both before and after the addition of insulin.
As shown in Figure 13B palmitate could not significantly reduce glycolysis in
Mk transgenic hearts but was effective in FVB hearts (Figure 13A),
demonstrating that regulation of F-2,6-P2 could overcome fat-induced
glycolytic inhibition. Both increased glycolysis caused by elevated F-2,6-P2 in
Mk mice and decreased

glycolysis caused by reduced 1F-2,6-P2 in Mb mice

produced detrimental actions in heart such as hypertrophy and cardiac
fibrosis as shown in figures 5, 6 and 7. Treatment with phenylephrine was
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also used to assess heart capabilities from FVB controll, Mb and Mk mice.
Phenylephrine usually increase cardiac afterload, as data in figure 10 shows
that stronger perivascular collagen deposits WEire found in FVB control mice
after being treated with phenylephrine for 28 days. Figure 8 shows higher
mortality in Mb and Mk transgenic mice, moreover, mortality of Mb mice was
slightly higher than that of Mk mice. When the mice were treated with
phenylephrine for :3 days, HE staining data in figure 8 shows cardiomyocyte
death in Mb and Mk mice but not in FVB control mice. Therefore, Both Mk
and Mb hearts seemed weaker ttlan those of FVB control mice.

Glucose toxicity and Lipid toxicity in Mb and Mk micE~

As illustrated in

Fi~lure

1 and 2, there is a balance between the

metabolism of glucose and that of fatty acid, which is called the Randle cycle.
Increased glucose utilization may inhibit fatty acid oxidation and result in the
accumulation of fatty acid in cytosol, while decreased glucose utilization may
enhance the fatty acid utilization and increase cellular oxidative stress. In Mk
transgenic mice, accumulation of fatty acid in cardiomyoctyes due to
increased glucose utilization could result in lipotoxicity as shown in Figure 3.
The lipotoxicity may cause cardiac dysfunction, apoptosis and insulin
resistance through multiple signal pathways, eventually resulting in cardiac
hypertrophy and heart failure. Increased glycolysis stimulated by F-2,6-P2
also can cause glucotoxicity, for which two pathways can be hypothesized,
one is by PKC, another is by AGE 55 . In Mb mice, decreased glycolysis will be
expected to increase fatty acid oxidation, and increased consumption of fatty
acids may provoke more ROS from mitochondria. Decreased glycolysis also
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can cause glucose toxicity through other pathways, one is to increase polyol
pathway influx, another is hexosamine pathwal 5 .
In Mb mice, reduced F-2,6-P2 will be expectHd to decrease the
activity of PFK-1, the upstream ml3tabolites of glycolysis at the point of PFK-1
may accumulate due to the reduced activity of PFK-1 such as F-6-P and/or
G-6-P and

glucose in cardiomyocytes. Accumulation of glucose in

cardiomyocytes could activate the polyol pathway and the accumulated
F-6-P could stimulate the hexosamine pathway. In the polyol pathway, aldose
reductase is the first enzyme and catalyses the NADPH-dependent reduction
of a wide variety of carbonyl compounds such as glucose to sorbitol, with
consumption of NADPH, anel further the sorbitol can be oxidized to fructose
by the enzyme sorbitol dehydrogenase, with NAD+ reduced to NADH

55.

In

this polyol pathway, NADPH is decreased and more glutathione (GSH)
needs to be generated, but too much consumption of GSH can increase
intracellular oxidative stress. The reduction of glucose utilization in Mb mice
leading to elevation of fatty acid utilization may also raise intracellular
oxidative stress. Therefore, oxidative stress (ROS) should be very high in Mb
mice. The increased intracHllular oxidative stress could activate multiple
signal pathways and could result in cell apoptosis and necrosis, leading to
cardiac dysfunction, hypertrophy and heart failure 6C1 , 86. In the hexosamine
pathway, the accumulated F-,6-P in Mb mice can be diverted from glycolysis
and be a substrate for glutamine:fructose-6-phosphate amino transferase
(GFAT) for producing glucosamine, and further forming UDP-N-acetyl
glucosamine (GlcNAc).The 'GlcNAc can modify various cytosolic proteins
and transcriptional factors by O-GlcNAcylation, either reducing or enhancing
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their activities,

which

are associated

with

development of diabetic

complications 65 . BE!CaUSe phosphorylation plays an important role in protein
activity and transcriptional activity, O-GlcNAcylation and phosphorylation
often occur reciprocally in transcription factors, thus O-GlcNAcylation
competing with phosphorylation may enhance or inhibit the transcriptional
activities, for example, Sp1 has shown some competing sites between
phosphorylation

and

O-C~lcNAcylation

affecting

Sp1

transcriptional

activities 65 ,96; A fourfold incrt3ase in O-acetylglucosaminylation of Sp1 result
in

a

reciprocal

30%

decrease

in

the

level

of

serine-threonine

phosphorylation of Sp 166 ; hyper~"ycemia can induce a .2.4-fold increase in
hexosamine pathway activity in aortic endothelial cells, resulting in a 1.7-fold
increase in Sp1 O-linked GIGNAc and a 70-80% decrease in Sp1 O-linked
phosphothreonine and phosphoserine 55 , 61, furthermore, hyperglycemia can
increase expression of an

8~;-base-pair

truncated PAI-1 promoter-Iuciferase

reporter DNA containing two Sp1 sites by 3.8 fold but fails to act when the
two Sp1 sites are mutated b5 ,

61.

Therefore, activation of the hexosamine

pathway by hyperglycemia may result in many changes in both gene
expression

and

protein

function,

which

together contribute

to

the

pathogenesis of diabetic cornplications 65 . In Mb mice, Sp1 activity may be
increased by the hexosamine pathway due to modification of Sp1 by
glycosylation. Sp1 activity is associated with gene expression of MMP, TIMP
and TGF-beta, PAI,-1, which are involved in cardiac remodeling and fibrosis
formation 88 .
In Mk transgene mice, increased F-.2,6-P2 will increase the activity
of PFK1, producing over amount of product F-1,6-F)2. The over amount of

42

F-1,6-P2 may exceed the capacities of downstream enzymes to metabolize
them, meanwhile F-1,6-P2 can balance reversibly with DHAP and GAP.
F-2,6-P2 probably lead to thE~ accumulation of

Therefore increased

dihydroxyacetone phosphatf3 (DIHAP) and GAP metabolites. Accumulated
GAP metabolites can form methylglyoxal, producing advanced glycolyation
endproducts (AGE). AGE formed from glucose is much sllower than that from
glucose-derived dicarbonyl precursors such as glyoxal, 3-deoxyglcosone
and methyglyoxal

84

.

In Mk mice, due to high activity of PFK-1, intracellular

methygloxal product could be hi!Jher than that in normal mice. The higher
methygloxal content inside cells, the more intracellular AGEs produced.
Intracellular AGE precursors can damage target cells by modifying
intracellular proteins, by altering intracellular protein function and activities,
and by modifying extracelluar matrix components interacting abnormally with
other matrix component and with receptors on cells suclh as intergrins, and
by modifying plasma proteins binding to AGE receptors, which activates
transcription

factor

NF-~:

B,

causing

pathological

changes

in

gene

expression 55 . DHAP accumulation will stimulate synthesis of (j-glycerol-P
with consuming NADH. The

(J

-glycerol-P reacting with fatty acid-CoA forms

phosphatidate. The phosphatidate can further be dHphosphorylated to
produce DAG. DAG can activate the conventional PKC isoforms (01,
calcium and activate novel PKC ilsoforms (0,
PKC isoforms (

Cl,

~,

£, 1"],

8

~,

y) with

) without calcium

72

, 73.

y). are up-regulated from the stage of cardiac

hypertrophy extending to congestive heart failure, but PKC isoform ( £) is
up-regulated especially in cardiac hypertrophy and declines in congestive
heart failure 72 . Hyperglycemia may activate PKC isoforms indirectly through
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both ligation of AGE receptors and the polyol path way 51. In addition, PKC
pathway also can be activated by autocrine/paracrine factors such as
TGF-beta, ET-1 and Ang " etc.

73

.

Activated PKCs have multiple adverse effects in diabetes, such as
cardiac hypertroph/ 3.

91.

For example, transgenic micE! with an increased

number of L-type calcium channels and PKCa activation develop cardiac
hypertrophy

and

severe

cardiac

dysfunction 82 ;

cardiac

specific

overexpression of PKCJ32 isoforrn can cause cardiac hypertrophy, fibrosis
and contractile dysfunction. The mechanism by which PKCJ32 damages
contractile function of heart is that PKCJ32 decreases cardiomyocyte calcium
sensitivity by phosphorylating troponin 195. Activation of the PKCE isoform
may lead to compensated ventricular hypertrophyB2 92. Elevated PKCo can
trigger cardiomyocyte apoptosis and necrosis by reducing ATP !generation
through inhibition of PDH, increasing ROS generation and increasing
cytochrome C release 56 .
Therefore, in Mb and Mk mice, the PKC pathway could bB activated
by ROS, hexosamine pathway, DAG and AGEs respectively or together.
The activated PKC pathway could result in necrosis and apoptosis of
cardiomyocytes, with results of cardiac dysfunction, hypertrophy and fibrosis.

Cardiac remodeling in Mb and Mk mice
In the heart, cardiac myocytes occupy 90% of the myocardial mass,
whereas

90-95<Yo

of

non

cardiomyocytes

are

cardiac

94
fibroblasts .

Cardiomyoctyes and non cardiomyoctyes are scaffolded by a network of
fibrillar collagen. Based on morphology, the network can be subdivided into
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three

components:

epimysium,

perimysium

and

endomysium.

The

epimysium surrounds the surfaces of the endocardial and the epicardial
myocardium, providing the support for endothelial and mesothelial cells. The
perimysium circles groups of muscle fibers and the endomysium, extended
from perimysium, surrounds individual fibers 87 . Fibrosis tissues can be
divided into three groups: perivascular fibrosis, interstitial fibrosis and
microscopic scarring 69 . Collagen is a stable protein whose synthesis and
degradation is normally slow (estimated to be 80-120 days) and is regulated
by cardiac fibroblasts 132 .
Under pathological conditions both the synthesis and degradation
of collagens are altered, and the accumulation of collagen results in fibrosis.
In morphologic terms, fibrosis can be classified as reactive fibrosis e.g., an
adverse accumulation of perimysial collagen, or as reparative fibrosis, which
fill in the empty space due to the death of cardiomyocytes for maintaining the
structural integrity of myocardium 53 69,85. Depending upon its location and
magnitude, collagen fiber crosslinking, and relative abundance of type I and

III collagens, fibroSIS can adversely increase myocardial stiffness, leading to
diastolic heart failure (DHF)85. In patients with hypertension, Extracellular
matrix (ECM) accumulation is associated with left ventricular hypertrophy
(LVH) and diastolic dysfunction and increases in ECM degradation seem to
precede the transition to systolic failure 85 . In animal models of hypertensive
heart disease (HHD), an increase in interstitial collagen (accumulated
perimysium) is associated with diastolic heart failure, whereas degradation of
endomysial and perimysial components of the collagen scaffolding is
accompanied by ventricular dilatation and systolic hE~art failure
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Both

intracellular and extracellular factors are involved in the remodeling process
(collagen synthesis and degradation). One component in this remodeling
process is a family of proteins called extracellular matrix

cjegradin~1

enzymes,

the matrix metalloproteinases (MMPs), another is a family of proteins called
tissue inhibitors of metalloproteinases (TIMPs). MMPs can degrade ECM
proteins with differing degrees of specificity, the collagenases (MMP1, MMP8,
and MMP13) initiate the ECM degradation process by cleaving the a-chains
of type I and type II collagens and the gelatinases (MMP2 and MMP9) further
process the collagen fragments 88 . The actual activity of MMPs depends
critically on the balance between active enzyme and TIMPs. TIMPs are
multifunctional proteins that can inhibit the catalytic activity of MMPs, thus
maintaining ECM homeostasis, for an example, TIMP-1 is a glycosylated
protein and is secreted in a soluble form, forming 1: 1 complex with MMP-9
78.

74,

A disordered balance of MMP and TIMP activity in HHD can exert

profound effects on cardiac function. For an example, the expression of
MMP-1 and TIMP-1 in cardiomyocytes is not found in normotensive subjects
but observed in heart failure hypertensive patients, furthermore, patients with
diastolic heart failure (OHF) exhibit low grades of MMP-1 expression and
patients with systolic heart failure (SHF) patients exhibit high grades of
MMP-1 expression. No differences in cardiomyocyte TIMP-1 expression
were observed between the two groups of patients. The expression of
MMP-1 and TIMP-1 in interstitial matrix is found among the three groups of
people: normal, OHF and SHF. However, the number of patients with high
grades of interstitial MMP-1 expression in SHF group are more than that in
OHF group. In contrast, the number of patients with high !Jrades of Interstitial
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TIMP-1 expression in DHF are more than that in SHF group

75.

lin addition,

MMP activation can contribute to the fibrotic process by participating in a
vicious circle in which ECM degradation promotes ECM protein synthesis
and fibrosis. This pathway is particularly detrimental because MMP can
degrade the native ECM very easily and the newly synthesized ECM which
usually are oxidized and highly cross linked collagen are diffilcult to be
degraded, favoring the accumulation of a much stiffer collagen

53.

Myofibroblasts, converted from fibroblasts, are responsible for the
synthesis of collagen and regulate collagen degradation through modifying
the balance of MMPs and their inhibitors (TIMPs). Myofibroblasts are defined
by their dual functions: fibroblast-like in terms of ECM synthesis and smooth
muscle myocyte-like in terms of migration. Myofibroblast formation is
controlled by growth factors, cytokines, and mechanical stimuli. Key
hormones and cytokines for this transition are ANG II, ET-·1, and T(3F-beta
79.

53,

Myofibroblast-mediated collagen turnover is regulated by autocrine and

paracrine factors generated within the myocardium and by endocrine
hormones derived from the circulation such as ET-1, Ang II, TGF-beta and
PAI_1 85 , 87.

94.

Taken together, these factors, which can be synthE!sized and

secreted by cardiomyocytes 58 ,

6:3, 83, 89, 90,

stimulate cardiac fibroblast

conversion to myofibroblast and regulate myofibroblast mediated collagen
turnover through modifying the balance of MMPs and TIMPs.
In cardiac specific lipoprotein lipase knock-out mice (hLPLO), fatty
acid utilization decreases and glucoses oxidation increase. The decreased
fatty acid utilization results in cardiac dysfunction such as diminishBd ejection
fraction and extensive fibrosis although glucose oxidation is increased,
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furthermore, expression of some genes associated with cardiac fibrosis and
matrix remodeling is increased such as TGF-beta, connective tissue growth
factor, TIMP-1, MMP-2 and pro-collagen 1 52.The decreased fatty acid
utilization and increased glucose oxidation are similar to that in Mk mice,
presumably Mk mice with hypertrophy and enhanced fibrosis should
accompany with same gene expression pattern as hLPLO mice in which
TGF-beta, connective tissue growth factor, TIMP-1, MMP-2 and pro-collagen
1 expression are upregulated.
In Mb mice, the hexosamine pathway modification of the Sp1
transcription factor by O-GlcNAcylation may increase the synthesis and
secretion of PAI-1 and TGF-beta, and high oxidative stress (ROS) could
activate NF-KB and AP-1 transcriptional factors. In Mk mice, elevated
glycolysis may increase ET-1 synthesis and secretion from cardiomyocytes,
and AGEs and DAG activate PKC pathway. PKC pathway activation would
turn on very complicated signal networks, such as increase of expression of
PAI-1, TGF-beta, NF-KB and AP-1 etc. These transcription factors mentioned
above could differentially regulate MMPs and TIMPs expression by binding
to the genes' promoter region, e.g. Sp'l for TIMP-1, TIMP-2, TIMP-3,TIMP-4
and MMP-2, MMP-9 and MT1-MMP; Ap-1 for MMPs, TIMP-1 and TIMP-2;
Ets for MMPs and TIMP-4; SMAD from TGF-beta for MMP-1, MMP-7,
MMP-13 and MT1-MMP; NF-KB for MMPS 59 ,88.
Plasminogen activator inhibitor-1 (PAI-1) is the major inhibitor of
tissue and urokinase plasminogen activators and thereby reduces the
conversion of plasminogen to plasmin, an extracellular protease that
mediates fibrinolysis and activates matrix metalloproteinases 58. RE~duction of
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plasmin in tissues will decrease the activation of MMPs, favorin9 collagen
accumulation. An elevated level of PAI-1 occurring in diabetes, insulin
resistance, obesity, and hypertension has been ascribed to be a risk factor
for development of cardiovascular disease 64 . 70.

76. 80.

In Mb mice, possible

increased PAI-1 sElcretion could inhibit plasmin formation and reduce the
activities of MMPs . In addition, increased Sp1 activity may alsCi raise the
expression of TIMP-1, TIMP-2, TIMP-3, TIMP-4, MMP-2, MMP-9 and
MT1-MMP, disrupting the normal balance of MMPs and TIMPs. Therefore,
O-GlcNAc Sp1 may be regarded as a very important factor involved in the
pathogenesis of Mb transgenic hearts.
Endothelin (ET)-1, a potEmt vasoconstrictor peptide from vascular
endothelial cells, is also synthesized and secreted by cardiomyocytes and
induces hypertrophy of cardiomyocytes

68,77.

The pattern of gene expression

of ET-1 reflects the level of the glycolytic system in cardiCimyocytes.
Enhanced glycolysis will upregulatl3 the cardiac gene expression of ET_1 59 , 71.
In Mk mice, high glycolysis may upregulate ET-1

expression. The

upregulated ET-1 may increase the expression of TIMP4 and MMPs,
affecting the balance of TIMPs with MMPs.
TGF-beta expression is increased in the patients with left ventricular
hypertrophy and dilated cardiomyopathy. Overexpression of TGF-beta
transgenic

mice

hypertrophl 9 ,
dysfunction

is

90.

demonstrates

that

TGF-beta

can

induce

cardiac

The mechanism by which TGF-beta causes cardiac
that

TGF-beta

stimulates

fibroblast

proliferation

and

conversion to myofibroblasts, and that TGF-beta induces the production of
ECM components through cardiac myofibroblasts and fibroblasts, and that
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TGF-beta can recruit smooth muscle cells, monocytes and fibroblasts and
stimulate wound repair and ECM deposition

93.

The nuclear factor SMAD

from TGF-beta stimulation can bind the promoter region of MMP-1, MMP-7,
MMP-13 and MT1-MP genes 88 . Therefore in Mb and Mk mice, TGF-beta may
be responsible for cardiac hypertrophy and fibrosis, probably through
regulating the gene expression of IV1MP-1, MMP-7, MMP-13 and MT1-MP.
In addition, increased intracellular oxidative stress in Mb mice and
PKC activation in Mk mice may a1fect the expression of several MMPs and
TIMPs, leading to unbalance of collagen synthesis and degradation 59 .

F-2,6-P2 involved in pathology of Mk and Mb mice

When cardiomyocytes were challenged by insulin in vitro, the signal
of P-AKT produced in Mk and Mb cardiomyocytes was significantly higher than
that of FVB control as shown in figure14, whereas the signals of P-4EBP1,
P-GSK-3b and P-IR were similar among cardiomyocytes from Mk, Mb and
FVB control mice. Our data suggest that F-2,6-P 2 is involved in insulin signal
pathway below P-IR and beyond P-AKT. Possibly some middle mediator
between P-IR and P-AKT such as IRS-1/2 or PI3K. may be affected by
F-2,6-P:z directly or indirectly. ThEl elevated P-AKT might be associated with
cardiac hypertrophy and matrix remodeling because P-AKT can increase
MMP-2 gene expression 81 . Cross talk between Ang II and the insulin signal
pathways occurs on the mediator IRS1/2. Both Insulin and Ang II stimulate the
tyrosine phosphorylation of insulin receptor substrates (IRS). IRS proteins act
as docking proteins for phosphatidylinositol 3-kinase (PI3-kinase) and growth
factor receptor-binding protein 2 (Grb-2), followed by signaling P-AKT from
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i7

Pl3-kinase or MAPKs from Grb-i

.

F-2,6-P2 could intensify the insulin signal

by elevating P-AKT. Possibly F-2,6-P2 can also intensify the Ang II signals,
which are associated with cardiac hypertrophy.

F-2,6-P2 not only regulates glucose metabolisms by allosteric effects
on PFK-1 but also regulates expression of key enzymes and transcriptional
factors. For example, when levels of F-2,6-P 2 are elevated in the liver,
glucose

kinase

(GK)

glucose-6-phosphotase

expression

(G6PasE~),

increased,

is

whereas

acetyl-CoA carboxylase( ACC) and fatty

acid synthase ( FAS) expression are reduced 47 .

Also affected as the

expression of some transcriptional factors are, such as reduction of ChREBP,
PPAR alpha, PGC-1 beta and SREBP
significantly

enlarge

cardiomyocytes

4',.

and

ET-1 has been shown to
PPARa

activator

linhibits

ET-1-induced increases in cardiomyocyte size 67 . In Mk mice, high glycolysis
may increase ET-1 secretion while high level of F-2,6-P2 may decrease the
expression of PPAR-a. Therefore, high level of F-2,6-P2 combined with
increased secretion of ET-1 could be responsible for Mk cardiac hypertrophy.
In summary, it is probable that multiple pathways are involved in the
observed

hypertrophy

and

fibrosis

of

Mk

and

Mb

mouse

hearts.

Transcriptional factors such as Sp'l, Ap1, SMAD and autocrine/paracrine
factors such as PAI-1, ET-1 and TGF-beta may be upregulated and/or
activated, regulating the balance of MMPs with TIMPs and affecting collagen
synthesis and degradation in Mk and Mb mice hearts. F-2,6-P2 may be
involved in the development of cardiac hypertrophy through Ang II signal
pathway or decreasing the expression of PPARa gene directly or indimctly.
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APPENDIX
ACC. acetyl-CoA carboxylase
ACS, acyl-CoA synthase
AGE, advanced glycollyation endproducts
AKT, protein kinase B
ANOVA, analyses of variance
AP-1, activating protein 1
aPK, atypical protein kinase
CAPP, ceramide-activated protein phosphatase
CAPK, ceramide-activated protein kinase
CD36, fatty acid translocase
ChREBP, carbohydrate response element -binding protein
CPT I,

palm Itoyltransferase

DAG, diacylglycerol
db/db mice, leptin receptor deficient mice
DHAP, dihydroxyacetone phosphate
DHF, diastolic heart failure

[eM, extracellular matrix
ET-1, endothelin -1,
Ets, E26 transformation-specific transcription factor
F-2,6-P2, fructose-2,6-bisphosphate
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F-6-P, fructose-6-phosphate
FA, fatty acid
FAS, fatty acid synthetase,
FABPpm, fatty acid binding protein plasma membrane
FAT, fatty acid transporter
FATP, fatty acid transport protein
FFA, free fatty acids
G3P,

glyceraldehyde<~-Phosphate

C,6P, glucose -6- phosphate
G-6-P, glucose-6-phosphate
G6Pase, glucose-6-phosphotase
GAP, D-glyceraldehyde 3-phosphate
GAPDH, glyceraldehyde phosphate dehydrogenase
(,FAT, glutamine:fructose-6-phosphate amino transferase
GK, glucose Kinase
GlcNAc, UDP-N-acetyl glucosamine
Glut1, glucose transporter 1
Glut4., glucose transporte 4
Grb-2, growth factor receptor-binding protein 2
C;SH, glutathione
HE staining, hematoxylin-eosin staining
HHD, hypertensive heart disease
HK, hexokinase,
hLPLO, lipoprotein lipase knock-out mice
IKB, inhibitor of NF-KB
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IRS, insulin receptor substrate
LPL, lipoprotein lipase
LVH, left ventricular hypertrophy
MAPKs, mitogen-activated protein kinases
MCO, malonyl-CoA decarboxylase
a-MHC, a-myosin heavy chain
~-MHC, ~-myosin

heavy chain, ,

MMPs, matrix metalloproteinases
NAOPH,

nicotinamidl~

adenine dinucleotide phosphate

NF-kB, nuclear factor-kappa B
PAI-1, plasminogen activator inhibitor-1
PARP, poly (AOP-ribose) polymerase
PBS, phosphate-buffered saline
POC , pyruvate decarboxylase
POH, pyruvate dehydrogenase
PE, phenylephrine
PFK-1, phosphofructose kinase-1
PFK-2, phosphofructose kinase-2
PGC-1 beta, peroxisome proliferator-activated receptor

~lamma

coactivator 1

beta
P-4EBP1, phosphorylation of eukaryotic translation initiation factor 4E binding
protein 1
P-AKT, phospho-AKT
P-GSK-3b, phosphorylation of glycogen synthase kinase 3 beta
PIP3, phosphatidylinositol (3,4,5) trisphosphate
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PI3K, phosphatidylinositol 3-kinase
P-IR, phospho insulin receptor
PKC, protein kinase C
PPAR-a, peroxisome proliferator-activated receptor-a
PS, penicillin-streptomycin
PTEN, phosphatase and tensin homologue deleted on chromosome 10
ROS, reactive oxygen species
SREBP, sterol-regulatory element-binding protein
SHF. systolic heart failure
Sp1, sequence-specific transcription factor 1
SMAD, mothers against decapentaplegic homolog
TCA cycle, citric acid cycle (Krebs cycle)
Tg, triglycerides
TGF-beta, transforming growth factor beta
TIMPs, tissue inhibitors of metalloproteinases
flU, microunit
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